All Stories

  1. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

    Article • Hepatology, April 2014, Wolters Kluwer Health

    Eric Hughes

  2. Virologic escape in HCV genotype 1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b

    Article • Antiviral Therapy, January 2014, International Medical Press

    Eric Hughes

  3. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection

    Article • Antiviral Therapy, January 2014, International Medical Press

    Eric Hughes

  4. Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1

    Article • Antiviral Therapy, January 2014, International Medical Press

    Eric Hughes

  5. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3

    Article • Journal of Hepatology, July 2013, Elsevier

    Eric Hughes

  6. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

    Article • Journal of Hepatology, April 2013, Elsevier

    Eric Hughes

  7. Randomized study of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 chronic hepatitis C

    Article • Antiviral Therapy, January 2013, International Medical Press

    Eric Hughes

  8. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

    Article • The Lancet Infectious Diseases, September 2012, Elsevier

    Eric Hughes, Dr Joseph K Lim

  9. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

    Article • Hepatology, March 2012, Wolters Kluwer Health

    Eric Hughes

  10. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients

    Article • Hepatology, October 2010, Wolters Kluwer Health

    Eric Hughes, Mrs Janke Schinkel

  11. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

    Article • Hepatology, August 2009, Wolters Kluwer Health

    Eric Hughes

  12. Necrotising cryptococcal vasculitis in an HIV‐negative woman

    Article • Mycoses, February 2006, Wiley

    Eric Hughes

  13. Immune Response to Salmonella

    Article • Immunity, March 2002, Elsevier

    Eric Hughes

  14. Thiol oxidation and reduction in MHC-restricted antigen processing and presentation

    Article • Immunologic Research, June 1999, Springer Science + Business Media

    Eric Hughes

  15. The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex

    Article • Current Biology, June 1998, Elsevier

    Eric Hughes

  16. Protein degradation: The ins and outs of the matter

    Article • Current Biology, September 1997, Elsevier

    Eric Hughes

  17. Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules

    Article • Nature, November 1992, Springer Science + Business Media

    Eric Hughes